Zacks Research Upgrades Nephros (NASDAQ:NEPH) to Hold

Nephros (NASDAQ:NEPH) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research report issued on Monday,Zacks.com reports.

A number of other equities analysts have also commented on NEPH. Weiss Ratings lowered shares of Nephros from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday. Northland Securities began coverage on Nephros in a report on Friday, July 17th. They issued a “market perform” rating and a $4.00 target price for the company. One research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $5.00.

Nephros Trading Down 2.4%

Shares of NEPH opened at $3.59 on Monday. The business’s 50-day moving average price is $3.47 and its 200 day moving average price is $3.63. The stock has a market capitalization of $38.98 million, a P/E ratio of 51.29 and a beta of 1.49. Nephros has a 1-year low of $2.66 and a 1-year high of $6.42.

Nephros (NASDAQ:NEPH) last announced its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, hitting the consensus estimate of $0.01. The company had revenue of $5.21 million during the quarter, compared to analysts’ expectations of $5.02 million. Nephros had a net margin of 4.06% and a return on equity of 7.66%. On average, research analysts predict that Nephros will post 0.03 earnings per share for the current year.

Institutional Investors Weigh In On Nephros

A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC grew its holdings in shares of Nephros by 3.2% during the 2nd quarter. Geode Capital Management LLC now owns 93,187 shares of the company’s stock valued at $381,000 after acquiring an additional 2,898 shares in the last quarter. Topline Capital Management LLC raised its holdings in shares of Nephros by 13.1% during the second quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock worth $1,953,000 after acquiring an additional 55,360 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in Nephros during the third quarter valued at $64,000. Citadel Advisors LLC boosted its position in Nephros by 39.2% during the third quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock valued at $78,000 after purchasing an additional 4,655 shares during the last quarter. Finally, Navellier & Associates Inc. purchased a new position in Nephros in the fourth quarter valued at about $133,000. Institutional investors and hedge funds own 41.10% of the company’s stock.

Nephros News Summary

Here are the key news stories impacting Nephros this week:

• Neutral Sentiment: Northland Securities reiterated a “Market Perform” rating on Nephros and set a $4.00 price target, which is only modestly above the recent trading range and suggests limited near-term upside. Nephros analyst estimates and rating update
• Neutral Sentiment: The firm’s updated earnings estimates point to gradual improvement, with Northland forecasting roughly $0.03 EPS for FY2026 and $0.19 EPS for FY2027, plus quarterly EPS in the low cents range through 2027. That outlook is constructive, but not strong enough to trigger a clear bullish re-rating on its own. Nephros earnings estimates update
• Neutral Sentiment: Nephros also announced it will participate in Maxim Group’s “Health, Wellness & Longevity” Virtual Conference on July 22. Conference participation can increase visibility, but it does not by itself change fundamentals. Nephros conference announcement

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.